Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Metformin has no Significant Anticancer Effect on Patients with Advanced or Unresectable Cancer: A Systematic Review and Meta-analysis

Author(s): Xinyan Gan, Chang Cao, Yan He, Xiaolin Hu, Xingchen Peng and Yonglin Su*

Volume 28, Issue 16, 2022

Published on: 20 May, 2022

Page: [1351 - 1358] Pages: 8

DOI: 10.2174/1381612828666220329113434

Price: $65

conference banner
Abstract

Background: At present, the antitumor effect of metformin is controversial. Previous meta-analyses included observational studies, of which the results can be influenced by many confounders, affecting the result of meta-analyses and weakening the strength of evidence. Therefore, we conducted a meta-analysis to confirm the effect of metformin use on patients with advanced or unresectable cancers, including randomized clinical trials (RCTs).

Methods: We searched for RCTs in accordance with the inclusion and exclusion criteria. A meta-analysis was conducted to combine hazard ratios (HRs) or risk ratios (RRs) and their 95% confidence intervals (CIs) using a random-effects model.

Results: Finally, 7 eligible RCTs were included in the meta-analysis. Overall, the combined results revealed that treatment with metformin did not improve the overall survival (OS) of patients (HR, 1.12; 95% CI, 0.91-1.37, p>0.05), and there was no clear evidence that metformin use was related to improved progression-free survival (PFS) (HR, 1.17; 95% CI, 0.97-1.40; p>0.05). The pooled RR for grade III or IV adverse events was 0.92 (95% CI, 0.52- 1.60; p>0.05), indicating that the use of metformin was not significantly related to increased toxicity.

Conclusion: Metformin does not significantly improve the survival of patients with advanced or unresectable cancer, regardless of cancer type and region.

Keywords: Metformin, cancer, randomized clinical trials, overall survival, progression-free survival, meta-analysis.

« Previous Next »
[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-49.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
Bradley CJ. Economic burden associated with cancer caregiving. Semin Oncol Nurs 2019; 35(4): 333-6.
[http://dx.doi.org/10.1016/j.soncn.2019.06.003] [PMID: 31229344]
[3]
Deng M, Su D, Xu S, et al. Metformin and vascular diseases: A focused review on smooth muscle cell function. Front Pharmacol 2020; 11: 635.
[http://dx.doi.org/10.3389/fphar.2020.00635] [PMID: 32457625]
[4]
Wu Y, Zheng Q, Li Y, et al. Metformin targets a YAP1-TEAD4 complex via AMPK alpha to regulate CCNE1/2 in bladder cancer cells. J Exp Clin Cancer Res 2019; 38.
[5]
Kleinberg DL, Wood TL, Furth PA, Lee AV. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 2009; 30(1): 51-74.
[http://dx.doi.org/10.1210/er.2008-0022] [PMID: 19075184]
[6]
Dowling RJO, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: Translational challenges. J Mol Endocrinol 2012; 48(3): R31-43.
[http://dx.doi.org/10.1530/JME-12-0007] [PMID: 22355097]
[7]
Fidan E, Onder Ersoz H, Yilmaz M, et al. The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Acta Diabetol 2011; 48(4): 297-302.
[http://dx.doi.org/10.1007/s00592-011-0276-y] [PMID: 21424914]
[8]
Wang JC, Li GY, Wang B, et al. Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation. J Exp Clin Cancer Res 2019; 38(1): 235.
[http://dx.doi.org/10.1186/s13046-019-1211-2] [PMID: 31164151]
[9]
Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA Cancer J Clin 2017; 67(5): 378-97.
[http://dx.doi.org/10.3322/caac.21405] [PMID: 28763097]
[10]
Haeusler RA, McGraw TE, Accili D. Biochemical and cellular properties of insulin receptor signalling. Nat Rev Mol Cell Biol 2018; 19(1): 31-44.
[http://dx.doi.org/10.1038/nrm.2017.89] [PMID: 28974775]
[11]
Gandini S, Puntoni M, Heckman-Stoddard BM, et al. Metformin and cancer risk and mortality: A systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) 2014; 7(9): 867-85.
[http://dx.doi.org/10.1158/1940-6207.CAPR-13-0424] [PMID: 24985407]
[12]
Park YMM, Bookwalter DB, O’Brien KM, Jackson CL, Weinberg CR, Sandler DP. A prospective study of type 2 diabetes, metformin use, and risk of breast cancer. Ann Oncol 2021; 32(3): 351-9.
[http://dx.doi.org/10.1016/j.annonc.2020.12.008] [PMID: 33516778]
[13]
Tseng CH. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus. Eur J Cancer 2014; 50(16): 2831-7.
[http://dx.doi.org/10.1016/j.ejca.2014.08.007] [PMID: 25201464]
[14]
Xiao K, Liu F, Liu J, Xu J, Wu Q, Li X. The effect of metformin on lung cancer risk and survival in patients with type 2 diabetes mellitus: A meta-analysis. J Clin Pharm Ther 2020; 45(4): 783-92.
[http://dx.doi.org/10.1111/jcpt.13167] [PMID: 32406122]
[15]
Shi J, Liu B, Wang H, Zhang T, Yang L. Association of metformin use with ovarian cancer incidence and prognosis: A systematic review and meta-analysis. Int J Gynecol Cancer 2019; 29(1): 140-6.
[http://dx.doi.org/10.1136/ijgc-2018-000060] [PMID: 30640696]
[16]
Shi YQ, Zhou XC, Du P, et al. Relationships are between metformin use and survival in pancreatic cancer patients concurrent with diabetes: A systematic review and meta-analysis. Medicine (Baltimore) 2020; 99(37): e21687.
[http://dx.doi.org/10.1097/MD.0000000000021687] [PMID: 32925714]
[17]
Rahmani J, Manzari N, Thompson J, et al. The effect of metformin on biomarkers associated with breast cancer outcomes: A systematic review, meta-analysis, and dose-response of randomized clinical trials. Clin Transl Oncol 2020; 22(1): 37-49.
[http://dx.doi.org/10.1007/s12094-019-02108-9] [PMID: 31006835]
[18]
Pimentel I, Lohmann AE, Ennis M, et al. A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. Breast 2019; 48: 17-23.
[http://dx.doi.org/10.1016/j.breast.2019.08.003] [PMID: 31472446]
[19]
Li L, Jiang L, Wang Y, et al. Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced NSCLC patients with EGFR mutations: A randomized, double-blind phase II trial. Clin Cancer Res 2019; 25(23): 6967-75.
[http://dx.doi.org/10.1158/1078-0432.CCR-19-0437] [PMID: 31413010]
[20]
Kordes S, Pollak MN, Zwinderman AH, et al. Metformin in patients with advanced pancreatic cancer: A double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 2015; 16(7): 839-47.
[http://dx.doi.org/10.1016/S1470-2045(15)00027-3] [PMID: 26067687]
[21]
Nanni O, Amadori D, De Censi A, et al. Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial. Breast Cancer Res Treat 2019; 174(2): 433-42.
[http://dx.doi.org/10.1007/s10549-018-05070-2] [PMID: 30536182]
[22]
Reni M, Dugnani E, Cereda S, et al. (Ir) relevance of Metformin treatment in patients with metastatic pancreatic cancer: An open-label, randomized Phase II trial. Clin Cancer Res 2016; 22(5): 1076-85.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-1722] [PMID: 26459175]
[23]
Nasser M. Cochrane handbook for systematic reviews of interventions. Am J Public Health 2020; 110: 753-4.
[http://dx.doi.org/10.2105/AJPH.2020.305609]
[24]
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16.
[http://dx.doi.org/10.1186/1745-6215-8-16] [PMID: 17555582]
[25]
Zhao Y, Gong C, Wang Z, et al. A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer. Oncotarget 2017; 8(48): 84224-36.
[http://dx.doi.org/10.18632/oncotarget.20478] [PMID: 29137418]
[26]
Sayed R, Saad AS, El Wakeel L, Elkholy E, Badary O. Metformin addition to chemotherapy in stage IV non-small cell lung cancer: An open label randomized controlled study. APJCP 2015; 16(15): 6621-6.
[PMID: 26434885]
[27]
Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res (Phila) 2010; 3(11): 1451-61.
[http://dx.doi.org/10.1158/1940-6207.CAPR-10-0157] [PMID: 20947488]
[28]
Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: A systematic review and meta-analysis. PLoS One 2012; 7(3): e33411.
[http://dx.doi.org/10.1371/journal.pone.0033411] [PMID: 22448244]
[29]
Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: A systematic review and meta-analysis. Oncologist 2013; 18(12): 1248-55.
[http://dx.doi.org/10.1634/theoncologist.2013-0111] [PMID: 24258613]
[30]
Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: A systematic review and meta-analysis. Ann Oncol 2016; 27(12): 2184-95.
[http://dx.doi.org/10.1093/annonc/mdw410] [PMID: 27681864]
[31]
Zeng S, Gan HX, Xu JX, Liu JY. Metformin improves survival in lung cancer patients with type 2 diabetes mellitus: A meta-analysis. Med Clin (Barc) 2019; 152(8): 291-7.
[http://dx.doi.org/10.1016/j.medcli.2018.06.026] [PMID: 30173870]
[32]
Yamamoto M, Patel NA, Taggart J, Sridhar R, Cooper DR. A shift from normal to high glucose levels stimulates cell proliferation in drug sensitive MCF-7 human breast cancer cells but not in multidrug resistant MCF-7/ADR cells which overproduce PKC-betaII. Int J Cancer 1999; 83(1): 98-106.
[http://dx.doi.org/10.1002/(SICI)1097-0215(19990924)83:1<98:AID-IJC18>3.0.CO;2-V] [PMID: 10449615]
[33]
Li S, Zhu H, Chen H, et al. Glucose promotes epithelial-mesenchymal transitions in bladder cancer by regulating the functions of YAP1 and TAZ. J Cell Mol Med 2020; 24(18): 10391-401.
[http://dx.doi.org/10.1111/jcmm.15653] [PMID: 32678516]
[34]
Villarreal-Garza C, Shaw-Dulin R, Lara-Medina F, et al. Impact of diabetes and hyperglycemia on survival in advanced breast cancer patients. Exp Diabetes Res 2012; 2012: 732027.
[http://dx.doi.org/10.1155/2012/732027] [PMID: 22919369]
[35]
Zhang M, Hu X, Kang Y, Xu W, Yang X. Association between fasting blood glucose levels at admission and overall survival of patients with pancreatic cancer. BMC Cancer 2021; 21(1): 131.
[http://dx.doi.org/10.1186/s12885-021-07859-9] [PMID: 33549043]
[36]
Wang NF, Tang HM, Liu FL, Hong QY. Prolonged progression-free survival and overall survival are associated with diabetes mellitus but inversely associated with levels of blood glucose in patients with lung cancer. Chin Med J (Engl) 2020; 133(7): 786-91.
[http://dx.doi.org/10.1097/CM9.0000000000000739] [PMID: 32195672]
[37]
Zhang ZJ, Yuan J, Bi Y, Wang C, Liu Y. The effect of metformin on biomarkers and survivals for breast cancer- a systematic review and meta-analysis of randomized clinical trials. Pharmacol Res 2019; 141: 551-5.
[http://dx.doi.org/10.1016/j.phrs.2019.01.036] [PMID: 30664988]
[38]
Tang GH, Satkunam M, Pond GR, et al. Association of metformin with breast cancer incidence and mortality in patients with type II Diabetes: A GRADE-assessed systematic review and metaanalysis. Cancer Epidemiol Biomarkers Prev 2018; 27(6): 627-35.
[http://dx.doi.org/10.1158/1055-9965.EPI-17-0936] [PMID: 29618465]

Rights & Permissions Print Cite
Article Metrics
23
1
© 2024 Bentham Science Publishers | Privacy Policy